This site is intended for healthcare professionals

News

Phase III trials show efficacy of EB 1020 in attention-deficit hyperactivity disorder.- Otsuka Pharmaceutical

Read time: 1 mins

Last updated:12th Jun 2020

Published:12th Jun 2020

Condition: Attention Deficit Hyperactivity Disorder

Type: drug

Register free for full access to medthority.com

Click here to register now